Table 1 Baseline characteristics in gastric cancer cases and controls
From: EBV antibody and gastric cancer risk: a population-based nested case-control study in southern China
Characteristics | Gastric cancer (N = 18) | Controls (N = 444) | Total (N = 462) | P† |
|---|---|---|---|---|
Sex, N (%) | 1.000 | |||
Female | 3 (16.7%) | 90 (20.3%) | 93 (20.1%) | |
Male | 15 (83.3%) | 354 (79.7%) | 369 (79.9%) | |
Age at recruitment, N (%) | 1.000 | |||
30 ~ 39 | 1 (5.6%) | 30 (6.8%) | 31 (6.7%) | |
40 ~ 49 | 2 (11.1%) | 60 (13.5%) | 62 (13.4%) | |
50 ~ 59 | 15 (83.3%) | 354 (79.7%) | 369 (79.9%) | |
Town, N (%) | 0.655 | |||
Gangkou | 2 (11.1%) | 40 (9.0%) | 42 (9.1%) | |
Minzhong | 4 (22.2%) | 53 (11.9%) | 57 (12.3%) | |
Xiaolan | 12 (66.7%) | 351 (79.1%) | 363 (78.6%) | |
Tumor histology | ||||
Adenocarcinoma | 8 (44.4%) | |||
Squamous cell carcinoma | 2 (11.1%) | |||
Unknown | 8 (44.4%) | |||
Tumor location | ||||
Cardia | 1 (5.6%) | |||
Non-cardia | 6 (33.3%) | |||
Unknown | 11 (61.1%) | |||
EBNA1-IgA, N (%) | 0.399 | |||
Negative | 16 (88.9%) | 422 (95.0%) | 438 (94.8%) | |
Positive | 2 (11.1%) | 22 (5.0%) | 24 (5.2%) | |
EBNA-IgA, rOD | 0.984 | |||
Median (Min, Max) | 0.18 (0.02, 5.49) | 0.19 (0.01, 2.57) | 0.19 (0.01, 5.49) | |
VCA-IgA, N (%) | 0.530 | |||
Negative | 16 (88.9%) | 418 (94.1%) | 434 (93.9%) | |
Positive | 2 (11.1%) | 26 (5.9%) | 28 (6.1%) | |
VCA-IgA, rOD | 0.137 | |||
Median (Min, Max) | 0.40 (0.14, 3.86) | 0.30 (0.03, 3.05) | 0.31 (0.03, 3.86) | |
Serological risk (combination of VCA-IgA and EBNA-IgA), N (%) | 0.031 | |||
Medium/Low | 15 (83.3%) | 431 (97.1%) | 446 (96.5%) | |
High | 3 (16.7%) | 13 (2.9%) | 16 (3.5%) | |
VCA-IgA and EBNA-IgA, N (%) | 0.422 | |||
Double negative | 14 (77.8%) | 398 (89.6%) | 412 (89.2%) | |
Single positive | 4 (22.2%) | 44 (9.9%) | 48 (10.4%) | |
Double positive | 0 (0%) | 2 (0.5%) | 2 (0.4%) |